Context Therapeutics LLC

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November:

Context Therapeutics to Participate in Upcoming Investor Conferences in November

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?

The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and reported on recent business highlights.

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipeline; however, it is being developed to go after oncofetal protein CLDN6, which is only highly expressed in embryonic tissue. With both phase 1 studies of CT-95 and CTIM-76 underway soon, it is highly likely that preliminary data from both trials could be released in 2025.

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, Inc. (“Link”), a mesothelin (“MSLN”) x CD3 T cell engaging (“TCE”) bispecific antibody with first-in-class potential that has received Investigational New Drug (“IND”) clearance from the U.S. Food and Drug Administration. CT-95 is on track for Phase 1 initiation in the first quarter of 2025.

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

ACM Research

Tidewater

Hypergrowth stocks are the holy grail of traders and growth investors. These stocks can multiply a small position by two, five, 10 times, or more.

Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight

Design Therapeutics

Revance Therapeutics

Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Does Context Therapeutics Inc. (CNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice

Context Therapeutics Inc. (CNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights. “We believe Context has had a great start to 2024 including achieving significant regulatory goals, demonstrating robust progress, and positioning us for future growth.

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers.

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Important Regulatory Milestone Supports Next Phase of CTIM-76 Development Important Regulatory Milestone Supports Next Phase of CTIM-76 Development

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended December 31, 2023, and reported on recent and upcoming business highlights. “During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study.

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Context Therapeutics (NASDAQ:CNTX) has announced its third-quarter results, highlighting its progress in advancing its lead candidate, CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, toward a first-in-human clinical study. The company said it remains on track to file an Investigational New Drug (IND) for CTIM-76 with the US Food and Drug Administration in the first quarter of 2024.

Context Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights. “During the third quarter of this year, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study.

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.  The biopharmaceutical company said findings from its research team, in conjunction with development partner Integral Molecular, illustrate the potential of CTIM-76 to treat CLDN6-positive tumors.

Context Therapeutics reveals ‘encouraging' preclinical data for CTIM-76 tumor treatment

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company's preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA.

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Context Therapeutics (NASDAQ:CNTX) Inc. has announced its financial results for the second quarter ended June 30, 2023, highlighting that it has sufficient cash and cash equivalents to continue funding operations into late 2024.

Context Therapeutic says it has enough cash to fund operation into late 2024

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming business highlights. “During the second quarter of this year, Context continued development of our preclinical asset CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody.

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023. Details of the events are as follows:

Context Therapeutics to Participate in Two August 2023 Investor Conferences

Ads-Tec Energy PLC

Applied Blockchain Inc

eFFECTOR Therapeutics Inc

Minerva Neurosciences

Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.

News for Context Therapeutics LLC Stock (CNTX)